O-.beta.. -D (and O-.alpha... -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
AssigneeAmerican Cyanamid Company
InventorsVijay G. Nair, Joseph P. Joseph, Arthur J. Lewis, Seymour Bernstein
Life of this patent
Estimating the term…
Abstract
O-.beta.-D (and O-.alpha.-D) multi-galactopyranosyl (or xylopyranosyl or glucopyranosyl) 1.alpha.,1.alpha.' galactopyranosyl (or xylopyranosyl or glucopyranosyl) sulfate salts, useful as complement inhibitors, the intermediates thereof and the process for preparation of such compounds.
Claims34
A compound selected from those of the formula:
- ##STR27## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C.sub.1 -C.sub.6), piperidine, pyrazine, alkanolamine (C.sub.2 -C.sub.6) and cycloalkylamine (C.sub.3 -C.sub.6);
- R and R', when they are the same, are selected from the group consisting of ##STR28## wherein A is as hereinabove defined;
- and R and R', when they are different, are each selected from the group consisting of --OSO.sub.3 A and ##STR29##
A compound selected from those of the formula:
- ##STR30## wherein M and P, when they are the same, are selected from the group consisting of ##STR31## and M and P, when they are different, are each selected from the group consisting of OH and ##STR32##
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula:
- ##STR33## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C.sub.1 -C.sub.6), piperidine, pyrazine, alkanolamine (C.sub.2 -C.sub.6) and cycloalkylamine (C.sub.3 -C.sub.6);
- R and R', when they are the same, are selected from the group consisting of ##STR34## wherein A is as hereinabove defined;
- and R and R', when they are different, are each selected from the group consisting of --OSO.sub.3 A and ##STR35##
A method of inhibiting the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula:
- ##STR36## wherein A is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C.sub.1 -C.sub.6), piperidine, pyrazine, alkanolamine (C.sub.2 -C.sub.6) and cycloalkylamine (C.sub.3 -C.sub.6);
- R and R', when they are the same, as selected from the group consisting of ##STR37## wherein A is as hereinabove defined;
- and R and R', when they are different, are each selected from the group consisting of --OSO.sub.3 A and ##STR38##
Dependencies are inferred from the claim text.